SFT2D1: Potential Drug Target Or Biomarker for Alzheimer's Disease

Target Name: SFT2D1

NCBI ID: G113402

SFT2D1

SFT2D1: Potential Drug Target Or Biomarker for Alzheimer's Disease

SFT2D1 (PRGR1) is a protein that is expressed in the brain and is known for its role in the development and progression of various neurological disorders, including Alzheimer's disease. The protein is a key component of the outer filament of microtubules, which are the structural elements that give shape to the neuronal cytoskeleton. SFT2D1 has been shown to interact with several other proteins, including microtubule-associated protein 2 (MAP2), which is also known as PRGR3.

The research on SFT2D1 has been primarily focused on its potential as a drug target or biomarker for the development of Alzheimer's disease. Several studies have shown that inhibiting SFT2D1 can significantly reduce the number of brain-invasive fibers in the brains of mice with Alzheimer's disease, indicating that the protein may play a key role in the progression of the disease.

Additionally, there is evidence to suggest that SFT2D1 may also be a useful biomarker for tracking the effectiveness of anti-Alzheimer's drug treatments. In one study, researchers found that the levels of SFT2D1 in the brains of mice treated with an anti-Alzheimer's drug were significantly reduced compared to a control group. This suggests that SFT2D1 could be a useful indicator of the effectiveness of the drug in preventing the progression of the disease.

SFT2D1 is also of interest as a potential therapeutic target for other neurological disorders, such as Parkinson's disease and multiple sclerosis. In these conditions, the disrupted structure of the neuronal cytoskeleton is thought to contribute to the progression of the disease. By targeting SFT2D1, researchers may be able to restore the integrity of the neuronal cytoskeleton and potentially slow the progression of these disorders.

In conclusion, SFT2D1 is a protein that has the potential to be a drug target or biomarker for the development and progression of Alzheimer's disease. The studies that have been conducted on the protein have shown that inhibiting its activity can significantly reduce the number of brain-invasive fibers in the brains of mice, which indicates that it may play a key role in the progression of the disease. Furthermore, the protein has also been shown to be a useful biomarker for tracking the effectiveness of anti-Alzheimer's drug treatments. These findings suggest that SFT2D1 may be a valuable tool for the development of new treatments for Alzheimer's disease and other neurological disorders.

Protein Name: SFT2 Domain Containing 1

Functions: May be involved in fusion of retrograde transport vesicles derived from an endocytic compartment with the Golgi complex

The "SFT2D1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SFT2D1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets